SCHEMBL11523980

SCHEMBL11523980

CCOc1ccc(OCC)c(NC)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.54
TSHR P16473 4/20 0.51
HTT P42858 2/20 0.51
ALDH1A1 P00352 2/20 0.51
LMNA P02545 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
NQO1 P15559 1/20 0.48
KDM4E B2RXH2 3/20 0.48
HPGD P15428 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPK1 P28482 2/20 0.47
PLAU P00749 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
CHEK1 O14757 1/20 0.45
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25683297 0.83 NQO1 (0.46) EPHX1TSHRHTTALDH1A1LMNA
SCHEMBL28517016 0.83 EPHX1 (0.52) EPHX1TSHRHTTALDH1A1LMNA
SCHEMBL25683657 0.81 NQO1 (0.48) EPHX1TSHRHTTALDH1A1NQO1
SCHEMBL19009072 0.80 L3MBTL1 (0.50) EPHX1TSHRHTTALDH1A1LMNA
SCHEMBL23033475 0.79 CALM1 (0.42) EPHX1TSHRHTTALDH1A1L3MBTL1
SCHEMBL11698830 0.79 GAA (0.56) TSHRHTTALDH1A1LMNAL3MBTL1
SCHEMBL9230295 0.79 NPC1 (0.47) EPHX1TSHRALDH1A1NQO1HPGD
SCHEMBL14350877 0.79 EPHX1 (0.63) EPHX1TSHRHTTALDH1A1LMNA
SCHEMBL9182141 0.78 EPHX1 (0.74) EPHX1TSHRHTTALDH1A1LMNA
SCHEMBL28501781 0.78 EPHX1 (0.52) EPHX1TSHRHTTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9757375-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-12 US disclosed
US-20170174639-A1 EIS INHIBITORS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2017-06-22 US disclosed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
US-20100099683-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-22 US disclosed
US-4172944-A Water insoluble styryl dyestuffs having hetero-aryl methylene substituent BAYER AKTIENGESELLSCHAFT (DE) 1979-10-30 US disclosed
US-4046771-A GREENISH-YELLOW SHADES ON SYNTHETIC FIBERS BAYER AKTIENGESELLSCHAFT (DT) 1977-09-06 US disclosed
US-4016191-A WATER INSOLUBLE; LIGHTFASTNESS BAYER AKTIENGESELLSCHAFT (DT) 1977-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174639-A1 EIS INHIBITORS ABCC1, ATP5ME, ABCG2 EPHX1 1778/4885TSHR 3072/4885HTT 4803/4885
US-20100099683-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER LIG1, LIG4, LIG3 EPHX1 3493/4885TSHR 4461/4885HTT 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.